Progenics Pharma (PGNX) Posts Q3 EPS of 51c

Progenics Pharma (NASDAQ: PGNX) reported Q3 EPS of $0.51, $0.67 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $41.66 million versus the consensus estimate of $2.5 million.

For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• SanDisk upgraded at JPMorgan after investor day; shares climb